alzheim
diseas
ad
common
fatal
neurodegen
diseas
nd
character
structur
function
loss
neuron
last
decad
ad
associ
risk
factor
becom
major
healthcar
concern
develop
countri
furthermor
report
ad
fifthlead
caus
death
among
age
year
incid
exce
five
million
case
per
year
unit
state
alzheim
associ
world
health
organ
estim
preval
ad
worldwid
quadrupl
reach
approxim
million
alzheim
associ
patholog
hallmark
ad
includ
progress
accret
plaqu
outsid
neuron
extracellular
amyloid
plaqu
neurofibrillari
tangl
insid
neuron
hyperphosphoryl
tau
protein
accumul
vanitalli
patholog
chang
gradual
result
neuron
loss
eventu
neuron
death
although
etiolog
pathogenesi
ad
remain
imprecis
amyloid
cascad
theori
wide
accept
support
sever
studi
drachman
herrup
hypothesi
reinforc
identif
protect
amyloid
precursor
protein
app
mutat
near
protein
betacleavag
site
protect
develop
late
onset
dementia
jonsson
et
al
amyloidbeta
amino
acid
residu
peptid
key
compon
extracellular
amyloid
plaqu
express
consid
key
event
ad
progress
li
et
al
peptid
product
sequenti
proteolyt
cleavag
app
typei
transmembran
protein
proteolyt
cleavag
result
gener
two
type
isoform
though
abund
human
fluid
aggreg
faster
consid
lethal
term
neuron
surviv
report
oligom
diffus
protofibril
prefibrillar
aggreg
diffus
ligand
addl
main
toxic
player
develop
progress
ad
haass
selko
shankar
et
al
funk
willbold
numer
amyloid
reduct
therapi
art
clinic
trial
fail
provid
expect
clinic
improv
ad
patient
failur
rais
genuin
concern
regard
valid
amyloid
cascad
hypothesi
merit
research
art
extanc
grundman
et
al
cheng
et
al
today
due
extens
effort
research
pharmaceut
compani
peptidebas
drug
emerg
major
class
therapeut
result
last
decad
wit
extraordinari
scientif
industri
interest
therapeut
use
vliegh
et
al
studi
much
ongo
current
number
natur
synthet
therapeut
peptid
undergo
clinic
trial
mandal
et
al
gener
drug
sever
advantag
small
molecul
therapeut
particularli
term
efficaci
fewer
side
effect
craik
et
al
mani
fatal
nd
parkinson
diseas
pd
amyotroph
later
sclerosi
al
prion
diseas
huntington
diseas
hd
share
ad
characterist
misfold
protein
aggreg
peptid
proven
vital
tool
nd
research
use
studi
properti
misfold
protein
andor
peptid
review
articl
discuss
avail
peptidebas
therapeut
use
treat
ad
use
peptid
inhibitor
target
differ
aspect
ad
use
peptid
diagnosi
earli
detect
ad
current
number
vivo
diagnost
techniqu
avail
detect
ad
limit
earli
detect
diseas
crucial
effect
treatment
preemptiv
treatment
might
control
elimin
earli
stage
diseas
investig
ad
patient
shown
amyloid
plaqu
appear
sever
year
cognit
symptom
silverman
et
al
thal
et
al
funk
willbold
accordingli
earli
stage
detect
quantif
amyloid
brain
view
import
prognost
point
view
evalu
effect
therapi
sever
molecular
imag
techniqu
includ
magnet
reson
imag
mri
positron
emiss
tomographi
pet
singlephoton
emiss
comput
tomographi
spect
provid
mean
molecular
imag
techniqu
report
use
detect
biomark
ad
mainli
monitor
express
frisoni
et
al
thu
attract
consider
attent
ad
research
field
furthermor
amyloid
ligand
use
contrast
agent
estim
amyloid
plaqu
load
shown
stain
amyloid
plaqu
specif
brain
tissu
ad
patient
make
peptid
suitabl
probe
vivo
imag
kang
et
al
denantiomer
peptid
also
known
deriv
anoth
set
peptid
report
bind
one
studi
also
found
bind
high
affin
submicromolar
rang
funk
et
al
et
al
current
use
molecular
probe
monitor
plaqu
load
live
brain
find
show
inject
brain
specif
bind
stain
dens
amyloid
deposit
brain
diffus
plaqu
van
groen
et
al
make
suitabl
molecular
probe
vivo
imag
ad
addit
recent
studi
describ
seri
denantiomer
peptid
also
specif
bind
aggreg
funk
et
al
greater
stabil
bind
properti
confirm
bind
peptid
deriv
ex
vivo
immunochemistri
perform
use
transgen
mous
model
ad
deriv
found
bind
aggreg
greater
affin
parent
find
suggest
compound
might
use
probe
specif
type
aggreg
plaqu
vivo
larbanoix
et
al
use
phage
display
techniqu
search
peptid
ligand
carri
abil
vector
aptarget
contrast
agent
identifi
peptid
ligand
among
sequenc
phage
clone
high
affin
two
peptid
select
cfrhmteqc
ciplpfync
found
present
sever
copi
kdvalu
picomolar
rang
exampl
ciplpfync
found
kd
valu
cfrhmteqc
kd
valu
mous
peptid
also
test
human
cfrhmteqc
demonstr
similar
affin
human
wherea
ciplpfync
demonstr
greater
affin
human
mous
addit
preliminari
vivo
mri
studi
transgen
mous
model
ad
show
cfrhmteqc
ciplpfync
act
excel
contrast
agent
larbanoix
et
al
amyloid
plaqu
accumul
fibril
clinic
hallmark
ad
hajipour
et
al
thu
inhibit
amyloid
aggreg
subject
much
research
last
two
decad
use
peptidebas
inhibitor
repres
major
part
effort
goyal
et
al
folch
et
al
figur
larg
number
studi
focus
design
peptid
fragment
capabl
bind
region
critic
aggreg
ladner
et
al
peptid
design
function
bind
either
prevent
fibril
format
elong
prevent
format
monomersoligom
long
list
peptid
specif
target
design
doig
eskici
gur
discuss
recent
report
peptid
inhibitor
tabl
show
import
peptid
describ
literatur
inhibitor
ad
peptid
inhibitor
share
sequenc
similar
hydrophob
segment
capabl
alter
aggreg
reduc
cytotox
wasmer
et
al
austen
et
al
describ
two
peptid
inhibitor
rgklvffgr
produc
modifi
klvff
amino
acid
sequenc
incorpor
residu
n
ctermin
inhibitor
report
effect
inhibit
fibril
format
anoth
studi
wei
et
al
report
new
peptid
inhibitor
base
modif
hydrophob
klvff
amino
acid
sequenc
synthes
conjug
pentapeptid
klvff
ferrocenoyl
fc
improv
lipophil
proteolyt
stabil
peptid
inhibitor
anoth
studi
rangachari
et
al
design
two
contain
peptid
base
klvff
found
two
novel
peptid
disrupt
aggreg
though
quit
differ
mechan
anoth
group
research
design
synthes
decapeptid
inhibitor
aggreg
inhibitor
ryyaaffarr
design
rr
unlik
inhibitor
design
target
extend
region
consist
gagbind
site
hydrophob
core
salt
bridg
region
rr
found
high
bind
affin
kd
bind
affin
markedli
greater
known
breaker
peptid
kd
liu
et
al
chalifour
et
al
report
result
obtain
replac
lamino
acid
damino
acid
aim
increas
peptid
stabil
therapeut
potenti
effect
chiral
revers
denantiom
assess
five
peptid
kklvffa
klvffa
kivffa
kfvffa
kvvffa
found
inhibit
aggreg
better
lpeptid
particular
denantiom
kklvffa
found
inhibit
neurotox
effect
significantli
l
counterpart
jagota
rajada
synthes
three
short
dpeptid
kklvffarrrra
pgklvya
kklvffa
base
residu
central
hydrophob
core
residu
examin
effect
aggreg
observ
suggest
dpeptid
effect
inhibit
fibrillogenesi
two
three
kklvffa
pgklvya
found
improv
surviv
transgen
c
elegan
betasit
app
cleav
enzym
human
aspartyl
proteas
believ
play
prime
role
gener
beta
amyloid
peptid
ad
characterist
bilob
structur
membranebound
aspartyl
proteas
open
activ
site
less
hydrophob
aspart
proteas
allow
substrat
residu
accommod
hong
et
al
turner
et
al
level
elev
brain
tissu
ad
patient
overexpress
cerebrospin
fluid
offer
possibl
biomark
earli
stage
diseas
overexpress
compet
initi
cleavag
app
furthermor
inhibit
halt
format
first
step
app
amyloidogen
process
compos
two
signatur
peptid
dtg
posit
dsgt
posit
come
togeth
form
activ
site
abil
inhibit
app
yan
et
al
peptid
deriv
sequenc
also
report
inhibit
app
process
possess
catalyt
domain
contain
pair
aspart
acid
residu
activ
site
product
block
inhibit
reduc
product
deplet
act
substrat
observ
product
diminish
defici
mice
support
view
inhibitor
reduc
level
vassar
dehydrogenas
gapdh
glycolyt
enzym
consider
interest
nd
research
especi
ad
recent
reveal
gapdh
interact
app
known
involv
ad
sunaga
et
al
bertram
et
al
butterfield
et
al
gapdh
undergo
divers
oxid
modif
control
structur
function
activ
ad
expos
oxid
stress
form
amyloidlik
aggreg
reduc
neuron
synaps
number
furthermor
insolubl
aggreg
gapdh
acceler
amyloidogenesi
neuron
cell
death
vitro
vivo
itakura
et
al
gapdh
aggreg
caus
cystein
oxid
intermolecular
disulfid
bond
reduc
catalyt
activ
nakajima
et
al
glycyllhistidylllysinecopp
ghkcu
natur
occur
peptid
human
plasma
stun
array
action
appear
counter
agingassoci
diseas
condit
plasma
concentr
ghkcu
ngml
age
decreas
ngml
age
pickart
et
al
interestingli
enzym
primarili
involv
gapdh
gene
silenc
also
belong
histon
deacetylas
hdac
protein
famili
select
hdac
inhibitor
shown
possess
neuroprotect
properti
anim
model
brain
diseas
suggest
potenti
therapeut
ad
fischer
et
al
glyproglu
gpe
present
plasma
brain
tissu
shown
neuroprotect
effect
anim
model
nd
hd
pd
ad
alexi
et
al
basic
structur
studi
suggest
gpe
interact
singl
sever
glu
receptor
type
bind
nmethyldaspart
nmda
receptor
sara
et
al
furthermor
ctermin
glu
gpe
requir
nmda
receptor
bind
bind
induc
potassiumevok
releas
dopamin
nigrostriat
dopaminerg
termin
acetylcholin
unknown
mechan
via
nmda
receptor
sara
et
al
alonso
de
diego
et
al
striatalenrich
tyrosin
phosphatas
step
express
neuron
striatum
neocortex
hippocampu
relat
structur
pelkey
et
al
target
signal
pathway
postsynapt
termin
excitatori
glutamaterg
synaps
lombroso
et
al
boulang
et
al
step
regul
variou
synapt
action
includ
glutam
receptor
traffick
play
critic
function
learn
memori
karasawa
lombroso
interestingli
recent
suggest
step
overact
ad
schizophrenia
carti
et
al
endogen
step
level
also
influenc
suscept
neuron
excitotox
affect
regul
synapt
protein
chang
synapt
conduct
via
synchron
dephosphoryl
multipl
substrat
regul
synapt
plastic
step
intracellular
tyrosin
phosphatas
tp
encod
gene
contain
signatur
consensu
sequenc
iv
hcxagxxr
st
g
cterminu
requir
catalyt
activ
bult
et
al
activ
motif
iv
hcxagxgr
st
also
call
ploop
hous
catalyt
cy
nucleophil
attack
hallmark
ptp
superfamili
furthermor
neuroprotect
endogen
tripeptid
gpe
report
protect
rescu
cell
death
modifi
analog
gpe
includ
modif
pro
andor
glu
residu
synthes
evalu
guan
gluckman
bind
acid
analog
found
better
neuroprotect
effect
infant
rat
compar
gpe
cacciator
et
al
potassium
channel
recent
identifi
potenti
target
ad
rangaraju
et
al
lowinu
et
al
rangaraju
et
al
conduct
studi
ad
nonad
patient
found
overexpress
frontal
cortic
ad
patient
thu
suggest
potassium
channel
consid
therapeut
target
ad
exampl
peptid
subsequ
design
target
norton
chandi
larg
amount
research
effort
result
advanc
diagnosi
treatment
ad
etiolog
consid
explain
amyloid
cascad
hypothesi
furthermor
gener
consid
earli
detect
ad
like
facilit
treatment
use
advanc
therapeut
approach
use
peptid
diagnosi
ad
offer
effect
mean
nevertheless
peptidebas
approach
requir
develop
enabl
earli
ad
effici
diagnos
properli
treat
ic
mhb
conceiv
idea
mhb
ka
gr
draft
review
manuscript
ic
mhb
ka
gr
critic
review
articl
ic
edit
languag
correct
error
within
manuscript
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
